Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sequential Skin
Singapore, Singapore
- Ownership
- Private
- Development stage
- Other
01
Overview
Sequential Skin has demonstrated feasibility and commercial success in combining genetic and skin microbiome analysis for personalized product recommendations, but does not have clinical drug results; it supports product claims via certified, in vivo human skin microbiome testing.
- Therapeutic areas
- OtherDermatology
- Modalities
- DeviceDNA testing kitDiagnostic kitMicrobial therapy (for product development and certification, not patient therapeutics)
- Industry
- Molecular Diagnostics
02
Partnerships
Genom (strategic partnership to expand microbiome testing in Balkans and Eastern Europe)IndieBio (accelerator)JLabsCorundum Systems BiologySOSVInnovate UKother distributors
Beyond the preview
Go deeper on Sequential Skin.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sequential Skin.